Gilead has announced a $300 billion deal with Dragonfly Therapeutics to advance natural killer (NK) cell therapy for use in cancer treatment. The deal will grant Gilead access to Dragonfly’s set of TriNKET compounds, which help NK and cytotoxic T cells target and kill cancer cells. This deal, one of several such moves in recent years, includes potential future payments to Dragonfly.
According to Phil Taylor of PharmaPhorum, “Along with the upfront payment, Dragonfly is in line for undisclosed opt-in payments and development, regulatory and commercial milestones, as well as royalties on sales if any drugs from the partnership reach the market. “
To learn more, click here.
(Source: PharmaPhorum, May 3rd, 2022)
